ABSTRACT
Neuroendocrine tumors, are a heterogeneous group of tumors with 40-90% liver metastases at the time of diagnosis, and this is one of the most important criteria for determining survival. Among the locoregional treatments, radioembolization has taken its place in current guidelines in neuroendocrine tumors that cannot be resected by surgical methods and progressed under treatment with somatostatin analogues. This review aimed to summarize the recent studies with also the place and importance of radioembolization in the treatment protocol.
References
1Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 2010;12:361-379.
2Frilling A, Modlin IM, Kidd Mavidson B, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014;15:e8-21.
3Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009;2009:CD007060.
4Fairweather M, Swanson R, Wang J, et al. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol 2017;24:2319-2325.
5Vilchez V, Gedaly R. Liver transplantation for the treatment of neuroendocrine liver metastases. Best Pract Res Clin Endocrinol Metab 2016;30:141-147.
6NCCN Guidelines Version 1.2019. Neuroendocrine and Adrenal Tumors. Published by the National Comprehensive Cancer Network, Plymouth Meeting, PA, USA. [2019; cited 2019 Oct 4]. https://www.nccn.org/professionals/physician_gls/ pdf/neuroendocrine_blocks.pdf.
7Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-752.
8Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-176.
9Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review. Eur J Radiol 2018;100:23-29.
10Sommer WH, Ceelen F, García-Albéniz X, et al. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol 2013;23:3094-3103.
11Braat AJAT, Kappadath SC, Ahmadzadehfar H, et al. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Cardiovasc Intervent Radiol 2019;42:413-425.
12Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27:4656-4663.
13Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
14Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016;387:968-977.
15Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology 2017;104:26-32.
16Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017;376:125-135.
17Yordanova A, Ahrens H, Feldmann G, et al. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. Clin Nucl Med 2019;44:e329-e335.
18Claringbold PG, Turner JH. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer Biother Radiopharm 2015;30:261-269.
19Ezziddin S, Meyer C, Kahancova S, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med 2012;53:1663-1669.
20King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008;113:921-929.
21Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Curr Treat Options Oncol 2017;18:14.
22Ngo L, Elnahla A, Attia AS, et al. Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes. Ann Surg Oncol 2021;28:1950-1958.
23Currie BM, Nadolski G, Mondschein J, et al. Chronic Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumor: Transarterial Chemoembolization versus Transarterial Radioembolization. J Vasc Interv Radiol 2020;31:1627-1635.
24Pollock RF, Brennan VK, Peters R, Paprottka PM. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther 2020;20:997-1009.
25Tsang ES, Loree JM, Davies JM, et al. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Can J Gastroenterol Hepatol 2020;2020:5104082.
26Ingenerf M, Kiesl S, Karim S, et al. 68Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE). Cancers (Basel) 2021;13:4321.
27Lawhn-Heath C, Fidelman N, Chee B, et al. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. J Nucl Med 2021;62:221-227.
28Braat AJAT, Kwekkeboom DJ, Kam BLR, et al. Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018;18:84.
29Braat AJAT, Bruijnen RCG, van Rooij R, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol 2020;21:561-570.
